* Precision BioSciences Inc reported a quarterly adjusted loss of $2.25​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of $-2.10. The mean expectation of six analysts for the quarter was for a loss of $1.92 per share. Wall Street expected results to range from $-3.27 to -79 cents per share.

* Revenue fell 95.6% to $576.00 thousand from a year ago; analysts expected $6.36 million.

* Precision BioSciences Inc's reported EPS for the quarter was a loss of $2.25​.

* The company reported a quarterly loss of $16.43 million.

* Precision BioSciences Inc shares had risen by 0.7% this quarter and lost 17.6% so far this year.

FORECAST CHANGES

* The mean earnings estimate of analysts had risen by about 7.9% in the last three months.​

* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Precision BioSciences Inc is $30.00 This summary was machine generated from LSEG data November 4 at 03:19 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,

MISSED

Sep. 30 2024 -1.92 -2.25 Missed

Jun. 30 2024 -1.50 4.67 Beat

Mar. 31 2024 -1.91 -0.35 Beat

Dec. 31 2023 -2.05 -4.06 Missed